Literature DB >> 26857397

Preconditioning of Nonlinear Mixed Effects Models for Stabilisation of Variance-Covariance Matrix Computations.

Yasunori Aoki1,2, Rikard Nordgren3, Andrew C Hooker3.   

Abstract

As the importance of pharmacometric analysis increases, more and more complex mathematical models are introduced and computational error resulting from computational instability starts to become a bottleneck in the analysis. We propose a preconditioning method for non-linear mixed effects models used in pharmacometric analyses to stabilise the computation of the variance-covariance matrix. Roughly speaking, the method reparameterises the model with a linear combination of the original model parameters so that the Hessian matrix of the likelihood of the reparameterised model becomes close to an identity matrix. This approach will reduce the influence of computational error, for example rounding error, to the final computational result. We present numerical experiments demonstrating that the stabilisation of the computation using the proposed method can recover failed variance-covariance matrix computations, and reveal non-identifiability of the model parameters.

Keywords:  computational stability; identifiability; non-linear mixed effects model; parameter estimation uncertainty; preconditioning

Mesh:

Year:  2016        PMID: 26857397      PMCID: PMC4779107          DOI: 10.1208/s12248-016-9866-5

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  6 in total

1.  Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; Alison H Thomson; Peter A Milligan; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

2.  Derivation of various NONMEM estimation methods.

Authors:  Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-10       Impact factor: 2.745

3.  Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.

Authors:  T K Bergmann; C Brasch-Andersen; H Gréen; M Mirza; R S Pedersen; F Nielsen; K Skougaard; J Wihl; N Keldsen; P Damkier; L E Friberg; C Peterson; W Vach; M O Karlsson; K Brosen
Journal:  Pharmacogenomics J       Date:  2010-04-06       Impact factor: 3.550

4.  A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A.

Authors:  Anne-Kristina Frobel; Mats O Karlsson; Janne T Backman; Kalle Hoppu; Erik Qvist; Paula Seikku; Hannu Jalanko; Christer Holmberg; Ron J Keizer; Samuel Fanta; Siv Jönsson
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

5.  Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS.

Authors:  Per-Henrik Zingmark; Charlotte Edenius; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

6.  Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.

Authors:  R J Keizer; M O Karlsson; A Hooker
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-06-26
  6 in total
  8 in total

1.  Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection.

Authors:  Yasunori Aoki; Daniel Röshammar; Bengt Hamrén; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-11-04       Impact factor: 2.745

2.  Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.

Authors:  Lene Alifrangis; Rik Schoemaker; Niels J Skartved; Rikke Hald; Clara Montagut; Scott Kopetz; Josep Tabernero; Michael Kragh; Janet R Wade
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-11-02       Impact factor: 2.745

3.  Parameter Identifiability of Fundamental Pharmacodynamic Models.

Authors:  David L I Janzén; Linnéa Bergenholm; Mats Jirstrand; Joanna Parkinson; James Yates; Neil D Evans; Michael J Chappell
Journal:  Front Physiol       Date:  2016-12-05       Impact factor: 4.566

4.  Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women.

Authors:  J Berkhout; J A Stone; K M Verhamme; M Danhof; T M Post
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-11-21

5.  Saddle-Reset for Robust Parameter Estimation and Identifiability Analysis of Nonlinear Mixed Effects Models.

Authors:  Henrik Bjugård Nyberg; Andrew C Hooker; Robert J Bauer; Yasunori Aoki
Journal:  AAPS J       Date:  2020-07-02       Impact factor: 4.009

6.  Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.

Authors:  Wan-Yu Chu; Kim V Annink; Karel Allegaert; Alwin D R Huitema; A Laura Nijstad; Christian A Maiwald; Michael Schroth; Loubna El Bakkali; Frank van Bel; Manon J N L Benders; Mirjam M van Weissenbruch; Anja Hagen; Axel R Franz; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2021-10-07       Impact factor: 6.447

Review 7.  Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials.

Authors:  Ralf-Dieter Hilgers; Malgorzata Bogdan; Carl-Fredrik Burman; Holger Dette; Mats Karlsson; Franz König; Christoph Male; France Mentré; Geert Molenberghs; Stephen Senn
Journal:  Orphanet J Rare Dis       Date:  2018-05-11       Impact factor: 4.123

Review 8.  Metaheuristics for pharmacometrics.

Authors:  Seongho Kim; Andrew C Hooker; Yu Shi; Grace Hyun J Kim; Weng Kee Wong
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-10-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.